taobanker
App Builder
Molson Coors is a pretty good business priced far too cheaply at 8.5x 2027 earnings, with well-structured, well-termed debt. The stock is suppressed because it is a consensus funding short, and terminal-risk concerns should evaporate as the market eventually agrees, as long as management avoids bad M&A. x.comÂ
Molson Coors' terminal decline in beer sales looks priced in, so returns from current levels should be fine, backed by a 4.5% dividend easily covered by cash flow. x.comÂ
Surging costs and tapped-out customers threaten Constellation Brands' beer business. Consumer companies loaded with debt and lacking pricing power are ones to avoid; Constellation Brands should drop below $100 before its next report. x.comÂ
Boston Beer is probably the easiest short: its top line is shrinking by high single digits while it trades at 25 times earnings. x.comÂ
Celsius may be 30% undervalued while Monster Beverage is 40% overvalued. If Celsius doubles revenue from $3.35 billion in 2026 to $6.7 billion in 2031 without more acquisitions, a big if, while lifting EBITDA margins to 31% and net margins to 24%, the stock has about 230% upside, a 24% CAGR, even at a conservative 10x EBITDA and 20x P/E. Monster is expected to grow EPS only 12% a year in 2027-28 yet trades at 37x forward earnings, when it should be no higher than 24x. x.com x.com x.com x.comÂ
Monster Beverage is a high-quality compounder that owns a large share of a growing global energy-drink market. Its debt-free balance sheet funds buybacks and expansion into new markets such as Europe and Latin America. HSBC believes the stock is undervalued and could rise as much as 31%. x.com x.comÂ
Celsius is cheap against its cash earnings. It trades at 13x cash earnings and 11x next year's, while beverage companies usually get 18x. Fair value is $44.37 to $56.47, or 18x next year's cash earnings give or take 12%, and the stock sits 35% below the low end, with a pullback zone at $25.33. This is a valuation read on reported earnings and revenue estimates only, with no fundamental work. x.comÂ
Coca-Cola looks like a great funding short, since nothing makes it immune to the risks that battered its staples peers. GLP-1 drugs, store brands, new entrants and supply-chain inflation should hit it too, and non-sugar drinks only slow the U.S. decline, though international has held up better. About 2% revenue growth is thin support for 25x earnings while peers sit at 2008 valuations; it could fall to 15x unless the other staples rebound dramatically. x.com x.com x.com x.com x.com x.com x.com … Show more
